Nrf-2-SLC7A11-GSH pathway
Nrf-2-SLC7A11-GSH pathway
Overview
The Nrf-2-SLC7A11-GSH pathway refers to a redox-regulatory signaling axis centered on Nrf2 (nuclear factor erythroid 2–related factor 2), SLC7A11 (the cystine/glutamate antiporter subunit xCT), and glutathione (GSH). In biomedical research, this pathway is commonly discussed as a functional module that controls cellular antioxidant capacity, cystine uptake, glutathione synthesis, and resistance or susceptibility to oxidative stress. By promoting SLC7A11 expression, Nrf2 can support intracellular cystine import and GSH production, thereby helping cells neutralize reactive oxygen species and limit lipid peroxidation.
This pathway is especially important in studies of ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation. When Nrf2-SLC7A11-GSH signaling is suppressed, cells may become more vulnerable to oxidative injury and ferroptotic death; when it is activated, cells often show improved antioxidant defense. As a result, the pathway is frequently investigated in cancer, neuroprotection, inflammatory injury, and metabolic stress, including contexts involving GPX4, reactive oxygen species, superoxide dismutase, MDA, and related oxidative stress markers.
Recent Publications Focus
Below is a summary of the newest research publications targeting Nrf-2-SLC7A11-GSH pathway (sorted by publication date).
Recent research reveals the Nrf-2-SLC7A11-GSH pathway as a central regulatory axis controlling cellular antioxidant defense and ferroptosis induction, with therapeutic applications spanning protective and anti-cancer contexts. Studies demonstrate that pharmacological Nrf2 activation and SLC7A11 upregulation provide cytoprotective benefits across diverse pathologies. Wedelactone-loaded exosomes activated the Nrf2/SLC7A11/GPX4 axis to ameliorate sepsis-induced liver injury [42381381], while omaveloxolone, an FDA-approved Nrf2 activator, upregulated the SLC7A11 cystine transporter (xCT) and other NRF2 target proteins in spinal muscular atrophy fibroblasts [42301137]. Similarly, 10-shogaol from ginger and carvacrol both functioned as novel Nrf2 activators, inducing antioxidant gene expression and providing anti-inflammatory benefits in viral infection and cardiac injury models, respectively [42270434, 42259137]. At the molecular level, liraglutide engaged the GLP-1R/NRF2 pathway to reduce oxidative stress and suppress NLRP3 inflammasome-mediated responses in postoperative cognitive impairment [42102962].
Conversely, suppression of the Nrf2/SLC7A11/GSH pathway has emerged as a potent strategy to induce ferroptosis for cancer therapy. Exosome-like nanovesicles from Scutellaria barbata induced hepatocellular carcinoma ferroptosis through direct inhibition of the Nrf2/SLC7A11/GPX4 pathway, leading to glutathione depletion, iron accumulation, and mitochondrial dysfunction [42209785]. Paris polyphylla saponin ξII suppressed the BECLIN1/SLC7A11 axis to trigger autophagy-associated ferroptosis in cervical cancer cells with superior safety compared to cisplatin [42162690]. The combination of paclitaxel and sunitinib synergistically downregulated SLC7A11 alongside other ferroptosis suppressors (GPX4 and FTH1), with genetic studies establishing SLC7A11 as a critical mediator—its knockdown sensitized cells to the combination while overexpression conferred resistance [41955701].
The dual therapeutic potential of this pathway is further illustrated by engineered approaches targeting pathway components. Engineered mesenchymal stem cell-derived exosomes overexpressing miR-142a-3p directly targeted the GSK3β/Nrf2/SLC7A11 axis to suppress ferroptosis and oxidative stress in osteoarthritis, providing cartilage protection in preclinical models [41637927]. A self-propelled molecular rocket carrying triptolide induced both apoptosis and ferroptosis in Herceptin-resistant breast cancer via the Nrf-2-SLC7A11-GSH pathway, demonstrating how pathway modulation can overcome drug resistance while sparing normal tissues [41789437]. Collectively, these studies establish the Nrf-2-SLC7A11-GSH pathway as a versatile therapeutic target, where pathway activation provides cytoprotection against oxidative stress and inflammatory damage, while pathway inhibition enables selective ferroptosis-driven cancer therapy.